CLINICAL TRIALS PROFILE FOR TOVORAFENIB

« Back to Dashboard

All Clinical Trials for TOVORAFENIB

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT05465174 ↗	Nivolumab and DAY101 for Treatment of Craniopharyngioma in Children and Young Adults	Not yet recruiting	Bristol-Myers Squibb	Phase 2	2022-09-01	The current study assesses the tolerability and efficacy of combination therapy with PD-1 (nivolumab) and pan-RAF-kinase (DAY101) inhibition for the treatment of children and young adults with craniopharyngioma.
NCT05465174 ↗	Nivolumab and DAY101 for Treatment of Craniopharyngioma in Children and Young Adults	Not yet recruiting	Day One Biopharmaceuticals, Inc.	Phase 2	2022-09-01	The current study assesses the tolerability and efficacy of combination therapy with PD-1 (nivolumab) and pan-RAF-kinase (DAY101) inhibition for the treatment of children and young adults with craniopharyngioma.
NCT05465174 ↗	Nivolumab and DAY101 for Treatment of Craniopharyngioma in Children and Young Adults	Not yet recruiting	Sabine Mueller, MD, PhD	Phase 2	2022-09-01	The current study assesses the tolerability and efficacy of combination therapy with PD-1 (nivolumab) and pan-RAF-kinase (DAY101) inhibition for the treatment of children and young adults with craniopharyngioma.
NCT05566795 ↗	DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients With Low-Grade Glioma Requiring First-Line Systemic Therapy	Not yet recruiting	SIOPe Brain Tumor Group LOGGIC Consortium	Phase 3	2022-10-01	This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of DAY101 monotherapy versus standard of care (SoC) chemotherapy in patients with pediatric low-grade glioma (LGG) harboring an activating rapidly accelerated fibrosarcoma (RAF) alteration requiring front-line systemic therapy.
NCT05566795 ↗	DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients With Low-Grade Glioma Requiring First-Line Systemic Therapy	Not yet recruiting	Day One Biopharmaceuticals, Inc.	Phase 3	2022-10-01	This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of DAY101 monotherapy versus standard of care (SoC) chemotherapy in patients with pediatric low-grade glioma (LGG) harboring an activating rapidly accelerated fibrosarcoma (RAF) alteration requiring front-line systemic therapy.

Clinical Trial Conditions for TOVORAFENIB

Condition Name

Condition Name for TOVORAFENIB
Intervention	Trials
Low-grade Glioma	2
High Grade Glioma (HGG) of the Brain With BRAF Aberration	1
RAS Mutation	1
High Grade Glioma (III or IV)	1

Condition MeSH

Condition MeSH for TOVORAFENIB
Intervention	Trials
Glioma	2
Histiocytosis	1
Melanoma	1
Colorectal Neoplasms	1

Clinical Trial Locations for TOVORAFENIB

Trials by Country

Trials by Country for TOVORAFENIB
Location	Trials
United States	9
Canada	2

Trials by US State

Trials by US State for TOVORAFENIB
Location	Trials
California	2
Tennessee	1
Pennsylvania	1
Oregon	1
Indiana	1

Clinical Trial Progress for TOVORAFENIB

Clinical Trial Phase

Clinical Trial Phase for TOVORAFENIB
Clinical Trial Phase	Trials
PHASE2	1
PHASE1	2
Phase 3	1

Clinical Trial Status

Clinical Trial Status for TOVORAFENIB
Clinical Trial Phase	Trials
Not yet recruiting	2
NOT_YET_RECRUITING	2
Recruiting	2

Clinical Trial Sponsors for TOVORAFENIB

Sponsor Name

Sponsor Name for TOVORAFENIB
Sponsor	Trials
Day One Biopharmaceuticals, Inc.	3
National Cancer Institute (NCI)	2
Daniel Morgenstern	1

Sponsor Type

Sponsor Type for TOVORAFENIB
Sponsor	Trials
Other	5
Industry	4
NIH	2